This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Problems with acute gout and gout prophylaxis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Pharmacological gout prophylaxis consists of either:

  • allopurinol - most widely prescribed drug for gout prophylaxis in the UK, or,
  • uricosuric agents:
    • probenecid
    • sulfinpyrazone

There are several issues concerning prophylactic treatment in patients with acute gout:

  • prophylactic treatments should not be commenced during an acute attack of gout

  • if a patient has an acute attack while taking prophylactic treatment then the prophylaxis is continued at the same dose and the acute attack treated as usual

  • initiation of prophylaxis may precipitate an acute attack; this is prevented by co-administering an NSAID or colchicine until one month after normalisation of the uric acid level (usually about 3 months prophylaxis)

Reference:

  1. Drug and Therapeutics Bulletin (2004); 42(5):37-40.

 

  1. BNF 10.1.4

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.